JAJanux Therapeutics, Inc. JANX · NASDAQ
$16.51 -4.68% (-$0.81)
- Market cap
- $1.06B
- Enterprise value
- $1.05B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 33.2x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -15.1%
- Gross margin
- 68.9%
- Net margin
- -321.8%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 2.39
- Free float
- 94.6%
About the company
Janux Therapeutics is a biotechnology company focused on developing advanced therapeutic methods for cancer immunotherapy. The company specializes in utilizing its platform, which combines antibody technology with targeted therapeutic agents, to enhance the body's natural defense against cancer cells. Janux is developing various products, including bioconjugates, that aim to specifically target and destroy cancer cells while minimizing side effects on healthy tissues.
Sector
Healthcare
Industry
Biotechnology
CEO
David Alan Campbell
Employees
113
Headquarters
San Diego
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number